KR102163285B1 - 메토트렉세이트를 이용한 면역 관용의 유도 - Google Patents

메토트렉세이트를 이용한 면역 관용의 유도 Download PDF

Info

Publication number
KR102163285B1
KR102163285B1 KR1020197033979A KR20197033979A KR102163285B1 KR 102163285 B1 KR102163285 B1 KR 102163285B1 KR 1020197033979 A KR1020197033979 A KR 1020197033979A KR 20197033979 A KR20197033979 A KR 20197033979A KR 102163285 B1 KR102163285 B1 KR 102163285B1
Authority
KR
South Korea
Prior art keywords
methotrexate
cells
treatment
matg
alemtuzumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197033979A
Other languages
English (en)
Korean (ko)
Other versions
KR20190132551A (ko
Inventor
알렉산드라 조셉
수전 리처즈
멜라니 러젝
리처드 가먼
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102163285(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Priority to KR1020207027913A priority Critical patent/KR102316283B1/ko
Publication of KR20190132551A publication Critical patent/KR20190132551A/ko
Application granted granted Critical
Publication of KR102163285B1 publication Critical patent/KR102163285B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
KR1020197033979A 2011-05-16 2012-05-03 메토트렉세이트를 이용한 면역 관용의 유도 Active KR102163285B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207027913A KR102316283B1 (ko) 2011-05-16 2012-05-03 메토트렉세이트를 이용한 면역 관용의 유도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486697P 2011-05-16 2011-05-16
US61/486,697 2011-05-16
PCT/US2012/036405 WO2012158362A1 (en) 2011-05-16 2012-05-03 Induction of immune tolerance by using methotrexate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137032882A Division KR20140040744A (ko) 2011-05-16 2012-05-03 메토트렉세이트를 이용한 면역 관용의 유도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207027913A Division KR102316283B1 (ko) 2011-05-16 2012-05-03 메토트렉세이트를 이용한 면역 관용의 유도

Publications (2)

Publication Number Publication Date
KR20190132551A KR20190132551A (ko) 2019-11-27
KR102163285B1 true KR102163285B1 (ko) 2020-10-08

Family

ID=47177257

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197033979A Active KR102163285B1 (ko) 2011-05-16 2012-05-03 메토트렉세이트를 이용한 면역 관용의 유도
KR1020137032882A Ceased KR20140040744A (ko) 2011-05-16 2012-05-03 메토트렉세이트를 이용한 면역 관용의 유도
KR1020207027913A Active KR102316283B1 (ko) 2011-05-16 2012-05-03 메토트렉세이트를 이용한 면역 관용의 유도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020137032882A Ceased KR20140040744A (ko) 2011-05-16 2012-05-03 메토트렉세이트를 이용한 면역 관용의 유도
KR1020207027913A Active KR102316283B1 (ko) 2011-05-16 2012-05-03 메토트렉세이트를 이용한 면역 관용의 유도

Country Status (28)

Country Link
US (3) US20140135337A1 (OSRAM)
EP (2) EP2709627B1 (OSRAM)
JP (3) JP6174572B2 (OSRAM)
KR (3) KR102163285B1 (OSRAM)
CN (4) CN103648501A (OSRAM)
AU (1) AU2012256281B2 (OSRAM)
BR (1) BR112013029501A2 (OSRAM)
CA (1) CA2835819A1 (OSRAM)
CL (1) CL2013003298A1 (OSRAM)
CO (1) CO6841993A2 (OSRAM)
DO (1) DOP2013000268A (OSRAM)
EC (1) ECSP13013081A (OSRAM)
ES (1) ES2836823T3 (OSRAM)
GT (1) GT201300278A (OSRAM)
IL (2) IL229245B (OSRAM)
MA (1) MA35165B1 (OSRAM)
MX (1) MX2013013445A (OSRAM)
MY (1) MY173304A (OSRAM)
NI (1) NI201300121A (OSRAM)
PE (1) PE20140469A1 (OSRAM)
PH (1) PH12013502256A1 (OSRAM)
PT (1) PT2709627T (OSRAM)
RU (1) RU2674036C2 (OSRAM)
SG (1) SG194802A1 (OSRAM)
TN (1) TN2013000472A1 (OSRAM)
UA (1) UA117556C2 (OSRAM)
WO (1) WO2012158362A1 (OSRAM)
ZA (1) ZA201308315B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139379A2 (en) * 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
MX2013013445A (es) 2011-05-16 2014-07-28 Genzyme Corp Induccion de tolerancia inmunologica utilizando metotrexato.
BR112015027291A8 (pt) 2013-05-03 2019-12-24 Selecta Biosciences Inc uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
IL295392A (en) * 2013-06-04 2022-10-01 Selecta Biosciences Inc Repeated administration of non-immunosupressive antigen specific immunotherapeutics
WO2016037164A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
JP2016213236A (ja) * 2015-04-30 2016-12-15 日東電工株式会社 半導体装置用フィルム、及び、半導体装置の製造方法
KR102753928B1 (ko) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
WO2018209300A1 (en) * 2017-05-12 2018-11-15 Duke University Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy
TWI821227B (zh) 2017-12-22 2023-11-11 美商健臻公司 胺甲喋呤誘發的免疫耐受性之生物標記
EP3980784A1 (en) 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
IL295415A (en) 2020-02-08 2022-10-01 Genzyme Corp Compositions and methods for treating pompe disease
EP4337958A1 (en) * 2021-05-13 2024-03-20 Genzyme Corporation Novel predictive biomarkers for secondary autoimmunity after lymphocyte depleting therapy
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155207A1 (en) * 2007-11-29 2009-06-18 Hariri Robert J Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders
US20100135992A1 (en) * 2006-03-02 2010-06-03 Alexion Pharmaceuticals, Inc. Prolongation of Survival of an Allograft by Inhibiting Complement Activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080325A (en) 1976-11-17 1978-03-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of methotrexate
US4558690A (en) 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
US5108987A (en) 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
DE4000154A1 (de) 1990-01-04 1991-07-11 Symbiotec Gmbh Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
TWI359665B (en) 2004-03-05 2012-03-11 Denki Kagaku Kogyo Kk Hyaluronic acid/methotrexate compound
US7884196B2 (en) 2004-10-06 2011-02-08 Oliver Lawless Vaccine composition comprising methylated DNA and immunomodulatory motifs
WO2008094937A2 (en) 2007-01-29 2008-08-07 Joslin Diabetes Center, Inc. Methods of modulating angiogenesis
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) * 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US20110229470A1 (en) 2008-10-08 2011-09-22 Cambridge Enterprise Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis
EP2362771A1 (en) 2008-11-07 2011-09-07 4Sc Ag Combinational therapy comprising dhodh inhibitor and methotrexate for treating autoimmune disease
MX2013013445A (es) 2011-05-16 2014-07-28 Genzyme Corp Induccion de tolerancia inmunologica utilizando metotrexato.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100135992A1 (en) * 2006-03-02 2010-06-03 Alexion Pharmaceuticals, Inc. Prolongation of Survival of an Allograft by Inhibiting Complement Activity
US20090155207A1 (en) * 2007-11-29 2009-06-18 Hariri Robert J Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clinical and Experimental Immunology, 152: 138-146 (2008)*

Also Published As

Publication number Publication date
ES2836823T3 (es) 2021-06-28
KR20190132551A (ko) 2019-11-27
EP2709627B1 (en) 2020-09-23
PT2709627T (pt) 2020-12-24
ECSP13013081A (es) 2015-04-30
JP2014513722A (ja) 2014-06-05
JP2018184466A (ja) 2018-11-22
US20230372347A1 (en) 2023-11-23
KR20200116543A (ko) 2020-10-12
NZ742216A (en) 2018-10-26
JP6381707B2 (ja) 2018-08-29
MA35165B1 (fr) 2014-06-02
EP2709627A4 (en) 2014-11-12
NZ617575A (en) 2016-10-28
MX2013013445A (es) 2014-07-28
AU2012256281A1 (en) 2013-11-28
JP2017141236A (ja) 2017-08-17
CL2013003298A1 (es) 2014-07-25
DOP2013000268A (es) 2014-01-31
IL276879B (en) 2022-06-01
CA2835819A1 (en) 2012-11-22
ZA201308315B (en) 2014-07-30
CN113209288A (zh) 2021-08-06
GT201300278A (es) 2015-02-12
RU2013155618A (ru) 2015-06-27
AU2012256281B2 (en) 2017-06-15
PH12013502256A1 (en) 2022-04-08
SG194802A1 (en) 2013-12-30
KR102316283B1 (ko) 2021-10-21
NI201300121A (es) 2014-02-28
CN110124039A (zh) 2019-08-16
IL229245A0 (en) 2014-01-30
BR112013029501A2 (pt) 2017-01-24
JP6694020B2 (ja) 2020-05-13
EP2709627A1 (en) 2014-03-26
IL276879A (en) 2020-10-29
MY173304A (en) 2020-01-14
EP3824890A1 (en) 2021-05-26
TN2013000472A1 (en) 2015-03-30
US11672802B2 (en) 2023-06-13
WO2012158362A1 (en) 2012-11-22
PE20140469A1 (es) 2014-04-23
NZ716716A (en) 2018-06-29
RU2674036C2 (ru) 2018-12-04
CO6841993A2 (es) 2014-01-20
US20200360385A1 (en) 2020-11-19
US20140135337A1 (en) 2014-05-15
CN103648501A (zh) 2014-03-19
KR20140040744A (ko) 2014-04-03
CN109620830A (zh) 2019-04-16
JP6174572B2 (ja) 2017-08-02
IL229245B (en) 2020-08-31
UA117556C2 (uk) 2018-08-27

Similar Documents

Publication Publication Date Title
US20230372347A1 (en) Induction of immune tolerance by using methotrexate
Kuwaki et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen
Miura et al. TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival
KR20210021101A (ko) Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
JP2010501556A (ja) 併用療法におけるｃｄ８３の使用
Rodrigo et al. Acute rejection following kidney transplantation: state-of-the-art and future perspectives
US20210236512A1 (en) Clozapine for the treatment of a immunoglobulin driven b cell disease
HK40053628A (en) Induction of immune tolerance by using methotrexate
HK40053503A (en) Induction of immune tolerance using methotrexate
HK40012743A (en) Induction of immune tolerance by using methotrexate
HK40007634A (en) Induction of immune tolerance by using methotrexate
OA16781A (en) Induction of immune tolerance by using methotrexate.
NZ617575B2 (en) Induction of immune tolerance by using methotrexate
HK1194668B (en) Induction of immune tolerance by using methotrexate
HK1194668A (en) Induction of immune tolerance by using methotrexate
NZ716716B2 (en) Induction of immune tolerance by using methotrexate
NZ742216B2 (en) Induction of immune tolerance by using methotrexate

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191118

Application number text: 1020137032882

Filing date: 20131211

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191219

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200626

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200928

Application number text: 1020137032882

Filing date: 20131211

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200929

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201005

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230822

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240823

Start annual number: 5

End annual number: 5